Evaluation of cuprimine ® and syprine ® for decorporation of 60Co and 210Po

Health Physics

Volumn 98, Issue 3, 2010, Pages 471-479

  Levitskaia, Tatiana G ^a   Creim, Jeffrey A ^a   Curry, Terry L ^a   Luders, Teresa ^a   Morris, James E ^a   Woodstock, Angela D ^a   Levinson, Barry ^b   Thrall, Karla D ^a  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b Aton Pharma Inc   (United States)

Author keywords

60 Co; Chelation; Contamination; Intake; Internal; Radionuclide

Indexed keywords

ANIMALIA; RATTUS;

CHELATING AGENT; COBALT; PENICILLAMINE; POLONIUM; TRIENTINE;

ANIMAL; ARTICLE; CHEMISTRY; HUMAN; ISOLATION AND PURIFICATION; MALE; RAT; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; CHELATING AGENTS; COBALT RADIOISOTOPES; HUMANS; MALE; PENICILLAMINE; POLONIUM; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TRIETHYLENETETRAMINE;

EID: 77049083471     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/HP.0b013e3181bcdf4f     Document Type: Article

References (44)

1. Andersen O. Principles and recent developments in chelation treatment of metal intoxication. Chem Rev 99:2683-2710; 1999.
2. Andersson KG, Mikkelsen T, Astrup P, Thykier-Nielsen S, Jacobsen LH, Schou-Jensen L, Hoe SC, Nielsen SP. Estimation of health hazards resulting from a radiological terrorist attack in a city. Radiat Protect Dosim 131:297-307; 2008.
3. Ansoborlo E, Amekraz B, Moulin C, Moulin V, Taran F, Bailly T, Burgada R, Henge-Napoli MH, Jeanson A, Den Auwer C, Bonin L, Moisy P. Review of actinide decorporation with chelating agents. Comptes Rendus Chimie 10(10 -11):1010 -1019; 2007.
4. Atanova NV, Dobrynina NA, Kiryanov YA, Nikolaeva LS, Sultanova VS. Complexation of Ln(3-) with D-penicillamine. Zhurnal Neorganicheskoi Khimii 41:245-249; 1996.
5. Bhattacharyya MH, Breitenstein BD, Metivier H, Muggenburg BA, Stradling GN, Volf V. Guidebook for the treatment of accidental internal contamination of workers. Radiat Protect Dosim 41:1- 41; 1992.
6. Blanusa M, Varnai VM, Piasek M, Kostial K. Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Current Medicinal Chem 12:2771-2794; 2005.
7. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407- 484; 1997.
8. Burgada R, Bailly T, Prange T, Lecouvey M. Synthetic strategy of new powerful tris-bisphosphonic ligands for chelation of uranyl, iron, and cobalt cations. Tetrahedron Lett 48:2315-2319; 2007.
9. Cassol A, Dibernardo P, Portanova R, Tolazzi M, Zananato PL. Thermodynamic and spectroscopic investigations on the interaction of uranyl(VI) with neurtral n-donors and o-donors in dimethyl-sulfoxide. J Chem Soc Dalton Trans 5:733-739; 1995.
10. 60Co. Health Phys 92:332-344; 2007.
11. Detty MR, Friedman AE, Oseroff AR. A mechanism for the oxidation of glutathione to glutathione disulfide with organotellurium (IV) and organoselenium (IV) compounds. A stepwise process with implications for photodynamic therapy and other oxidative chemotherapy. J Org Chem 59:8245- 8250; 1994.
12. Ferguson CD, Kazi T, Perera J. Commercial radioactive sources: surveying the security risks. Monterey, CA: Center for Nonproliferation Studies, Monterey Institute of International Studies; Occasional Paper No. 11; 2003. Available at: http://cns.miis.edu/pubs/opapers/op11/op11.pdf. Accessed 22 February 2009.
13. Gorden AEV, Xu J, Raymond KN, Durbin P. Rational design of sequestering agents for plutonium and other actinides. Chem Rev 103:4207- 4282; 2003.
14. Gregus Z, Klaassen CD. Disposition of metals in rats: a comprehensive study of fecal, urinary, and biliary excretion and tissue distribution of eighteen metals. Toxicol Appl Pharm 85:24 -38; 1986.
15. Griffith WH, Pavcek PL, Mulfrod DJ. The relation of the sulfur amino acids to the toxicity of cobalt and nickel in the rat. J Nutrition 23:603- 612; 1942.
16. Gupta VK, Ali I. Determination of stability constants of Fe(II), Co(II), and Cu(II)-nitriloacetate-penicillamine mixed complexes by electrophoresis. Talanta 46:197-201; 1998.
17. Hans BJ, Hurst GG, LeBlanc RB, Meibohm AW. Inorganic complex compounds containing polydentate groups. VI. Formation constants of complex ions of diethylenetriamine and triethylenetetramine with divalent ions. J Phys Chem 56:16 -19; 1952.
18. Harman B, Sóvágó I. Metal complexes of sulphur-containing ligands. V. Interactions of cobalt(II) ion with L-cysteine and its derivatives. Inorganica Chimica Acta 80:75- 83; 1983.
19. Harrison J, Leggett RW, Lloyd D, Phipps A, Scott B. Polonium-210 as a poison. J Radiol Prot 27:17- 40; 2007.
20. Huang CC. Parkinsonism induced by chronic manganese intoxication-an experience in Taiwan. Chang Gung Med J 30:385-395; 2007. Available at: http://www.cgmh.org.tw/cgmj/3005/300501.pdf. Accessed 15 December 2009.
21. Hursh JB. The effect of BAL on the excretion and tissue distribution of polonium in rats. J Pharmacol Exp Ther 103:450-459; 1951.
22. Institute for Biosecurity, Saint Louis University School of Public Health. Dirty bomb-quick reference material. Radiological terrorism factsheet. Available at:
23. dirty/quick.htm. Accessed 23 February 2009.
24. Leggett RW. The biokinetics of inorganic cobalt in the human body. Sci Total Environ 389:259 -269; 2008.
25. Leggett RW, Eckerman KF. A systemic biokinetic model for polonium. Sci Total Environ 275:109 -125; 2001.
26. Marcus Y. Ion properties. New York: Marcel Dekker; 1997.
27. Merck & Co., Inc. Cuprimine-. Whitehouse Station, NJ: Merck; Publication 7873244; 2007. Available at: http://www.cuprimine.com/. Accessed 6 January 2010.
28. Moore MR, Imray P, Dameron C, Callan P, Langley A, Mangas S, eds. Copper. Report of an International Meeting, 20-21 June 1996. National Environmental Health Forum Monographs. Adelaide, South Australia: South Australian Health Commission; 1997.
29. National Council on Radiation Protection and Management. Management of persons accidentally contaminated with radionuclides. Bethesda, MD: NCRP; Report No. 65 1980.
30. National Institute of Standards and Technology. Standard Reference Database 46. NIST critically selected stability constants of metal complexes: Version 8.0. Gaithersburg, MD: NIST 2009. Available at: http://nist.gov/srd/ nist46.htm. Accessed 14 January 2009.
31. National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press; 1996.
32. Pearson RG. Hard and soft acids and bases. J Am Chem Soc 85:3533-3539; 1963.
33. Phan G, Le Gall B, Grillon G, Roult E, Fouillit M, Benech H, Fattal E, Deverre JR. Enhanced decorporation of plutonium by DTPA encapsulated in small PEG-coated liposomes. Biochimie 88:1843-1849; 2006.
34. Rencova J, Volf V, Jones MM, Singh PK. Decorporation of Po from rats by new chelating agents. Radiat Protect Dosim 53:311-313; 1994.
35. Rorabacher DB. Statistical treatment for rejection of deviant values: critical values of Dixon's "Q" parameter and related subrange ratios at the 95% confidence level. Anal Chem 63:139 -146; 1991.
36. Stradling GN, Hengé-Napoli M-H, Paquet F, Poncy J-L, Fritsch P, Taylor DM. Approaches for experimental evaluation of chelating agents. Radiat Protect Dosim 87:19 -27; 2000.
37. Stypinski-Mis B, Anderegg G. The stability of palladium(II) complexes with sulphur-containing ligands. Analytica Chimica Acta 406:325-332; 2000.
38. Taylor DM, Stradling, GN, Hengé-Napoli M-H. The scientific background to decorporation. Radiat Protect Dosim 87:11-17; 2000.
39. Taylor DM, Stradling GN, Menetrier F. Biokinetics of radionuclides and treatment of accidental intakes. Radiat Protect Dosim 105:637- 640; 2003.
40. U.S. Food and Drug Administration. Prussian Blue [ferric hexacyanoferrate (II)] for treatment of internal contamination with thallium or radioactive cesium. Washington, DC: U.S. FDA; 2003. Available at: http://www.fda.gov/Drugs/ EmergencyPreparedness/BioterrorismandDrugPreparedness/. Accessed 6 January 2010.
41. U.S. Food and Drug Administration. Calcium-DTPA and Zinc-DTPA. Washington, DC: U.S. FDA; 2004. Available at: http://www.fda.gov/cder/drug/ infopage/dtpa. Accessed 14 January 2009.
42. U.S. Food and Drug Administration. Guidance for industry. Internal radioactive contamination-development of decorporation agents. Washington, DC: U.S. FDA, Center for Drug Evaluation and Research; 2006a. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071944.pdf. Accessed 6 January 2010.
43. U.S. Food and Drug Administration. Potassium iodide. Washington, DC: U.S. FDA; 2006b. Available at: http://www.fda.gov/Drugs/EmergencyPreparedeness/ BioterrorismandDrugPreparedness/. Accessed 6 January 2010.
44. Yan QY, Anderegg G. The stability of the palladium(II) complexes with linear tetraamines. Inorganica Chimica Acta 105:121-128; 1985.